$14.46
+0.56 (+4.03%)
Open$14.24
Previous Close$13.90
Day High$14.49
Day Low$13.76
52W High$18.24
52W Low$7.48
Volume—
Avg Volume5.54M
Market Cap2.19B
P/E Ratio—
EPS$-3.86
SectorBiotechnology
Analyst Ratings
Buy
23 analysts
Price Target
+107.9% upside
Current
$14.46
$14.46
Target
$30.06
$30.06
$17.22
$30.06 avg
$35.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 166.56M | 159.79M | 165.80M |
| Net Income | 26.40M | 27.52M | 28.79M |
| Profit Margin | 15.9% | 17.2% | 17.4% |
| EBITDA | 53.49M | 47.96M | 56.14M |
| Free Cash Flow | 17.32M | 22.87M | 17.57M |
| Rev Growth | +0.5% | -2.4% | +23.6% |
| Debt/Equity | 0.62 | 0.47 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |